Experience

ARCH Venture Partners Co-Leads Xaira Therapeutics $1 Billion Series A Funding

April 24, 2024

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.

Related contacts

David Peinsipp
Partner, San Francisco
Colleen Badgley
Partner, Seattle
Danielle Naftulin
Partner, Palo Alto
Willy Cowles
Associate, Seattle
Bill Christiansen
Partner, Seattle
Dr. Tian Yong Zheng
Patent Agent, Seattle
Chen Chen
Associate, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Zack Gong
Associate, Shanghai
Tom James
Associate, San Francisco
Thomas Welk
Senior Counsel, San Diego
Carly Robinson
Associate, Reston
Sharon Connaughton
Special Counsel, Washington, DC

Related Practices & Industries

MediLink Therapeutics Announces Strategic Collaboration, Worldwide License Agreement With BioNTech

October 12, 2023

Cooley advised MediLink Therapeutics, a clinical-stage biotech company focused on developing globally competitive conjugated drugs, on its strategic research collaboration and worldwide license agreement with BioNTech.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Chen Chen
Associate, Palo Alto
Jennifer Raab
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Xiaozhen (Shawn) Yu
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

Zion Pharma Announces Sale of Lead Program to Roche

May 15, 2023

Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Aaron Pomeroy
Partner, Colorado
David Burns
Special Counsel, Washington, DC
Xiaoyu Xu
Associate, Beijing
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

Tmunity Therapeutics Agrees to Sell to Kite

December 28, 2022

Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.

Read more

Related contacts

Mark Weeks
Partner, Palo Alto
Ben Beerle
Partner, San Francisco
Marya Postner
Partner, Palo Alto
Chen Chen
Associate, Palo Alto
Jenny Ge
Associate, Los Angeles Santa Monica
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Los Angeles Santa Monica
Todd Gluth
Partner, San Diego
Kate Hillier
Partner, Seattle
Phil Mitchell
Partner, New York
Howard Morse
Partner, Washington, DC
David Walsh
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Stella Sarma
Special Counsel, Brussels
Andrew Bae
Associate, Washington, DC
Baasit Bhutta
Associate, Colorado
Paula Fleckenstein
Associate, Reston
John Forrest
Associate, Boston
Joyce Li
Associate, Chicago
Lindsey O'Crump
Associate, Washington, DC
Patrick Sharma
Associate, Los Angeles Santa Monica
Rubin Waranch
Associate, Colorado
Freddy Yip
Associate, Hong Kong

Related Practices & Industries

View more

Admissions & credentials

California